Crescent Biopharma, Inc. (CBIO) stock

CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30

$14.15−0.22 (-1.53%)

Close on Nov 13, 2026Market cap $525.59MP/E –Yield –

Crescent Biopharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Crescent Biopharma's price to sales ratio was 430.9× on Feb 29, 2016.

Period	Period end	Value	Change (pts)
2016	Feb 29, 2016	430.9×	−43.2
2014	Apr 30, 2014	474.1×	–

Parsed from the XBRL in Crescent Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Jun 16, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CBIO.

Advertisement
300 × 250

See a number that looks wrong?